Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
US-9102661-B2 · Aug 11, 2015 · US
Procaspase 3 activation by combination therapy
US11833147B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11833147-B2 |
| Application number | US-202117144926-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 8, 2021 |
| Priority date | Mar 6, 2012 |
| Publication date | Dec 5, 2023 |
| Grant date | Dec 5, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer comprising administering to a subject in need thereof an effective amount of PAC-1: and an effective amount of sunitinib, wherein sunitinib is synergistic with PAC-1 in the treatment of the cancer, wherein PAC-1 has a concentration of about 2.5 μM to about 10 μM, sunitinib has a concentration of about 100 nM to about 10 μM, and the cancer is a carcinoid tumor. 2. The method of claim 1 wherein the PAC-1 is administered orally. 3. The method of claim 1 wherein the sunitinib is administered orally. 4. The method of claim 3 wherein, the concentration of PAC-1 is about 5 μM to about 10 μM, and the concentration of sunitinib is about 2.5 μM to about 10 μM. 5. The method of claim 1 wherein PAC-1 and sunitinib are administered sequentially. 6. The method of claim 1 wherein PAC-1 and sunitinib are administered concurrently.
Assignees
Inventors
Classifications
Indoles, e.g. pindolol · CPC title
Cyclodextrins; Derivatives thereof · CPC title
having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title
Non-condensed pyrazines · CPC title
- A61K31/495Primary
having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11833147B2 cover?
- The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combi…
- Who is the assignee on this patent?
- Univ Illinois, Vanquish Oncology Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/495. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).